menu
    • menu
    [{"orgOrder":0,"company":"Rumpus Therapeutics","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Oncology","graph2":"Phase III","graph3":"Rumpus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumpus Therapeutics \/ Rumpus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Rumpus Therapeutics \/ Rumpus Therapeutics"},{"orgOrder":0,"company":"Rumpus Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumpus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumpus Therapeutics \/ Aytu BioScience","highestDevelopmentStatusID":"4","companyTruncated":"Rumpus Therapeutics \/ Aytu BioScience"}]

    Find Clinical Drug Pipeline Developments & Deals by Rumpus Therapeutics

    Menu

    Rumpus Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rumpus Therapeutics

                            U.S.A arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Rumpus Therapeutics

                            U.S.A arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Aytu BioScience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeu...

                            Details : Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 04, 2021

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Aytu BioScience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rumpus Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed

                            Rumpus Therapeutics

                            U.S.A arrow
                            Pharmaconex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Denovo Biopharma Enters into Option Agreement with Rumpus Therapeutics for Selected DB102 (Enzastaurin) Clinic...

                            Details : Rumpus Therapeutics gains the option to acquire an exclusive license to develop and commercialize DB102 worldwide for rare genetic pediatric onset or congenital disorders outside of oncology.

                            Product Name : Kinenza

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 21, 2020

                            Lead Product(s) : Enzastaurin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Denovo Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth